MedImmune Fortifies Strategic Scientific Portfo...

GAITHERSBURG, Maryland, May 6 /PRNewswire/ --

    MedImmune today announced that it has enhanced its leadership team to
guide the company's expanded product pipeline in the United States and abroad
as well as the core scientific research that underpins this development.
Jacqueline Hall has been appointed global vice president, product development
team leadership; Lorin Roskos, Ph.D. has been appointed vice president and
global head of pharmacokinetics (PK), pharmacodynamics (PD), and bioanalysis
in translational sciences and Beth Wensley has been appointed vice president,
project management. In addition, Erik-Jan Dekker, Ph.D. joined the
organization as vice president, international regulatory affairs, vaccines
and Reginald Seeto, M.D., joins as vice president, global strategic marketing
and portfolio management.


    "It is imperative that we have strong leaders who can channel the
continued growth of our product portfolio, particularly as we seek to build
out the organization globally," said David M. Mott, chief executive officer
and president. "Jacqui, Lorin, Beth, E-J and Reg have the innate talent,
industry experience and drive for results that will contribute to MedImmune's
continued leadership in biologics."



    Based at MedImmune's Cambridge, UK site, Ms. Jacqueline Hall is
accountable for the strategic leadership of global product development teams
that are responsible for the generation and execution of development plans
for biologics products. She joined Cambridge Antibody Technology (CAT), now
MedImmune, in 2006 as vice president, project management. Previously, Ms.
Hall served as project leader at GlaxoSmithKline where she was responsible
for the strategic development of product candidates from selection through to
market launch. She has also held positions at SmithKline Beecham,
Pharmaco-LSR and Schering-Plough. Ms. Hall has a first-class honors degree in
chemistry from Imperial College of Science and Technology/Birbeck College,
London and a diploma in clinical science from the Welsh School of Pharmacy,
Cardiff.



    Dr. Lorin Roskos is responsible for managing and integrating preclinical
and clinical PK/PD and bioanalytical groups at MedImmune sites in Maryland,
California and England. Dr. Roskos became part of the MedImmune team in 2008
after a year at AstraZeneca as executive director of research and
development. Prior to AstraZeneca, Dr. Roskos spent six years at Abgenix,
Inc., as the head of PK and toxicology, and has prior experience in PK and
drug metabolism at Amgen and Eli Lilly. He holds a doctorate in pharmaceutics
from the University of Washington and a bachelor's degree in biochemistry and
pharmacy from the University of Georgia.



    Ms. Beth Wensley oversees the global project management team that
provides strategic project management in driving forward the product
development teams and the overall product development portfolio. Ms. Wensley
joined MedImmune in 2001, and has previously served as senior director,
California operations; director, supply chain operations; and associate
director, project management. She earned extensive project management,
operational, manufacturing and environmental, health & safety experience
during her tenure with companies such as Incyte Genomics, Raychem Corporation
and Syntex Pharmaceuticals. She holds a master's degree in business
administration from Santa Clara University and a master's in environmental
science from the University of Washington. She also has a bachelor's degree
in biology from California Lutheran College and is APICS certified from the
Association for Operations Management.



    Based in the Netherlands as MedImmune's new vice president, international
regulatory affairs, vaccines, Dr. Erik-Jan Dekker is leveraging his 17 years'
experience in regulatory affairs to lead MedImmune's expansion overseas. In
his previous position at Baxter Healthcare, he was the global senior
director, regulatory affairs, biologics, responsible for worldwide vaccine
and biosurgery marketing authorization applications. Prior to joining Baxter
Healthcare, Dr. Dekker was the director of regulatory affairs globally at
Laboratoire Francais du Fractionnement et des Biotechnologies in France.
Earlier in his career, Dr. Dekker held teaching positions at the University
of Utrecht and Alkwin College. From the University of Utrecht, Dr. Dekker
holds a doctorate in biochemistry and molecular developmental biology and
genetics, a master's degree in biology and international patent law and a
bachelor's degree in biology and geography.



    As MedImmune's new vice president, global strategic marketing and
portfolio management, Dr. Reginald Seeto is responsible for providing
strategic guidance on investment decisions and managing commercialization
efforts for new products in various stages of development. In his previous
position at Organon International, he was the vice president of global
marketing, fertility, immunology, oncology and vaccines. Previously, Dr.
Seeto was the executive director of marketing at Boehringer Ingelheim
Pharmaceuticals and had served as an engagement manager at McKinsey &
Company. He holds both a medical degree and a bachelor of science degree from
the University of Sydney, and practiced medicine in Australia early in his
career.



About MedImmune

    MedImmune strives to provide better medicines to patients, new medical
options for physicians and rewarding careers to employees. Dedicated to
advancing science and medicine to help people live better lives, the company
is focused on infection, oncology, respiratory disease and inflammation,
cardiovascular/gastrointestinal disease and neuroscience. With approximately
3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly
owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit
MedImmune's website at http://www.medimmune.com.



Web site: http://www.medimmune.com